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Background: Familial adenomatous polyposis (FAP) is usually characterised by the appearance of hundreds-to-thousands
of adenomas throughout the colon and rectum and if left untreated the condition will develop into CRC with close to
100% penetrance. Germline mutations in the APC gene, which plays an integral role in the Wnt-signalling pathway,
have been found to be responsible for 70-90% of FAP cases. Several studies suggest that modifier genes may play an
important role in the development of CRC and possible modifiers for FAP have been suggested. Interestingly, a study
has found that SNPs within ATP5A1 is associated with raised levels of ATP5A1 expression and high expression levels may
facilitate CRC development. We aimed to determine if SNPs in ATP5A1 modify the risk of developing CRC/adenomas in
FAP patients.
Methods: Genomic DNA from 139 Australian FAP patients with a germline APC mutation underwent genotyping at
the Australian Genome Research Facility (AGRF) utilising iPLEX GOLD chemistry with Sequenom MassArray on an
Autoflex Spectrometer for 16 SNPs in the ATP5A1 gene. Association between ages of diagnosis/risk of CRC/adenomas
was tested with Kaplan-Meier estimator analysis, logistic regression and cox proportional hazard regression.
Results: An association between age of diagnosis of CRC and genotypes was observed for SNP rs2578189 (p = 0.0014),
with individuals harbouring the variant genotype developing CRC 29 years earlier than individuals harbouring the
wildtype genotype. Individuals harbouring the variant genotype of SNP rs2578189 were also at increased risk of CRC
(HR = 13.79, 95% CI = 2.36-80.64, p = 0.004). We used an independent Dutch FAP cohort (n = 427) to validate our results;
no association between SNP rs2578189 and CRC was observed.
Conclusion: These results highlight the difficulties in studying a disease that has a high degree of intervention and
also emphasize the importance of large sample sizes when searching for modifier genes in patients with an inherited
predisposition to disease. To fully determine if there are genetic modifiers of disease in FAP we would encourage
people that are interested in collaborating in future studies into the role of modifier genes in disease expression in FAP
to join forces.
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Colorectal cancer (CRC) is one of the most common and
preventable forms of cancers worldwide, with an annual
incidence of ~16,000 and accounting for ~4,000 deaths in
Australia alone [1]. Several genetic and environmental fac-
tors contribute to the development of cancer and it is esti-
mated that up to 35% of all CRCs are caused by a genetic
predisposition [2]. Familial adenomatous polyposis (FAP)
accounts for approximately 1% of all CRCs [3] and is an
inherited autosomal-dominant condition characterised by
the appearance of hundreds to thousands of adenomas
throughout the colon and rectum [3]. The disease has
almost 100% penetrance and if left untreated will ulti-
mately develop into CRC by the third or fourth decade of
life. Extra-colonic manifestation occur in approximately
70% of FAP patients [4] and include desmoid tumours,
congenital hypertrophy of the retinal pigment epithelium
(CHRPE), hepatoblastoma, fundic gland polyps, pancreatic
and thyroid cancers, dental abnormalities and malignant
tumours of the central nervous system [3,5,6].
Truncating germline mutations in the adenomatous
polyposis coli (APC) gene are responsible for 70-90% of
FAP cases [7]. APC plays an integral role in the Wnt-
signalling pathway, especially in regards to the degradation
of β-catenin within the cell cytoplasm. Considerable varia-
bility in disease expression is observed within families and
among individuals with identical mutations exist [8] and it
has been shown that the greater the number of colorectal
adenomas, the greater the CRC risk is [9]. Even though
haplotype reconstructions from pedigrees found no evi-
dence for a specific APC haplotype associated with disease
severity [10], genotype-phenotype correlations have been
associated with the location of germline mutations within
APC that are related to the severity of polyposis and
expression of extra-colonic features [7,11]. Patients with
mutations in the mutation cluster region (MCR), located
between codons 1286 to 1513 [12], have generally a worse
prognosis with earlier onset of disease [13]. Most severe
disease is associated with germline mutations at codon
1309 [14], while milder forms of disease with less
than 100 adenomas and later ages of onset (attenuated
FAP (AFAP)) is associated with codons <157, 312–412
and >1595 [11,15].
Several studies suggest that low-penetrant susceptibility
genes may play an important role in the development of
sporadic CRC [16-21]. There is evidence to show that
variation in FAP severity, which has been shown to be in-
dependent of APC mutation and most likely the action of
modifier genes, is expected to result in different rates of
tumour initiation (adenoma number) rather than diffe-
rences in tumour progression i.e. adenomas to carcinoma
[22]. Modifier genes can influence individual susceptibility
to cancer by enhancing or supressing the initiation,
growth and/or progression of tumour cells. The pattern ofintrafamilial variation in colonic FAP severity is consistent
with the action of modifier genes [10,22-24].
Interestingly, a study has found that the ATP5A1 gene
(chromosome 18q21) may act as a modifier gene in the
development of CRC in the murine version of human
FAP (APCMin mice) [25]. The gene has previously been
shown to suppress polyp formation in mice when it is
mutated, with mutant Atp5a1 mice showing a reduction
in small intestinal and colonic polyps by approximately
90% [26]. Unexpectedly, this mutation has also shown
that more adenomas progress to carcinomas in Min
mice that carry the Atp5a1 mutation [25]. The ATP5A1
gene encodes the alpha-subunit of ATP synthase, a
multi-subunit enzyme which resided on the mitochon-
drial membrane. Absence of ATP5A1 leads to a non-
functional α-synthesis subunit and subsequent apoptosis
of the cell [27]. Raised levels of ATP5A1 expression have
been associated with certain single nucleotide polymor-
phisms (SNPs) and high expression levels together with
chromosome instability (CIN) may facilitate CRC deve-
lopment [28]. This study aims to investigate if SNPs in
the ATP5A1 gene can act as modifiers for CRC develop-
ment in FAP patients.
Methods
Sample cohort
Genomic DNA from 139 FAP patients from 86 families
with a molecular diagnosis of FAP (carriers of germ-
line APC mutations) was obtained from the Hunter
Area Pathology Service (HAPS), John Hunter Hospital,
Newcastle, New South Wales, Australia. All samples
were collected between the years 1997 and 2008. Each
participant (n = 139) had previously contributed blood
from which DNA was extracted using the salt precipita-
tion method [29]. All the participants in the study have
given informed consent for their de-identified DNA to be
used for future research into the cause of their condition.
Ethics approval was obtained from Hunter Area Research
Ethics Committee and the University of Newcastle
Human Research Ethics Committee.
Genotyping
The genotyping was outsourced to the Australian Genome
Research Facility (AGRF) who utilised iPLEX GOLD
chemistry with Sequenom MassArray on an Autoflex
spectrometer to genotype 16 SNPs in ATP5A1 (18q21);
rs13381709, rs1800636, rs1800637, rs1800639, rs1800640,
rs2298787, rs2578187, rs2578189, rs7244921, rs8088881,
rs8089150, rs8092674, rs8093880, rs8094902, rs8095031
and rs8095608.
Statistical analysis
A Pearson’s Chi-square test was used to evaluate deviation
from the expected Hardy-Weinberg equilibrium (HWE).
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disequilibrium as 137/139 samples have the exact same
genotypes; we are therefore only testing three SNPs and
applied Bonferoni correction for multiple testing resulting
in a corrected significance threshold of: p = 0.05/3 = 0.0167.
Risk of CRC association with each SNP was estimated by
heterozygous and homozygous odds ratio (OR) using sim-
ple logistic regression and multiple logistic regressions to
adjust for gender (male; female) and mutation group ac-
cording to severe (APC MCR = codons 1250–1513), atte-
nuated (APC AFAP = codons <157, 312–412 and >1595)
and intermediate (APC = the rest of the gene) polyposis
phenotypes. Kaplan-Meier estimator analysis was used to
test association between age of diagnosis of CRC and
genotypes. Age of diagnoses of CRC were used as estimate
functions, while age at last follow up was used for can-
cer free individuals. Wilcoxon’s (Breslow), Log-rank and
Tarone-Ware tests were used to examine homogeneity of
the Kaplan-Meier plots. All three tests were required to be
significant for results to be considered reliable but only
log-rank test is reported in Table 1. If a SNP was found to
be associated with risk of CRC/adenomas through logistic
regression/Kaplan-Meier, association between genotype
and risk of CRC/adenomas was further evaluated using
Cox proportional hazard model. Clustering of samples
within families were adjusted for by including family as a
frailty term in the model, if there was more than one
member of a family, patients were grouped together as
one ‘cluster’.
Validation cohort
To confirm the significant association observed in the
Australian FAP cohort for SNP rs2578189 we recruited an
independent Dutch FAP cohort from Leiden University
Medical Centre. Genotyping of rs2578189 was outsourced
to KBioscience (England, UK) who genotyped 427 FAP
patients with a germline APC mutation from 182 Dutch
families with a KASP assay. Due to extensive follow-up
and surveillance of this FAP cohort, we were able to divide
the patients into two groups, those that developed cancer
and those who developed adenomas. Furthermore, we
defined AFAP as <100 adenomas and Classic FAP as
according to the presence of >100 adenomas.
Results and discussion
As cancer development in general is known to be in-
fluenced by both genetic and environmental factors, it is
important to explore the possibility of different genes
being involved in modifying the expression of disease in
FAP patients - as patients harbouring identical mutations
in APC can have very different disease profiles that cannot
be explained by environmental factors alone. Identification
of FAP patients with a modifying genotype is important
for the implementation of screening strategies at an earlyage to remove premalignant adenomas that are likely to
be associated with disease development. As it has been
suggested that raised levels of ATP5A1 expression have
been linked to certain SNPs and high expression levels
may facilitate CRC development [28], we aimed to study
several SNPs in this gene to determine whether they in-
fluence the age of diagnosis or risk of developing CRC.
Association testing between disease severity and ATP5A1
The genotype frequency distribution for the different
SNPs in this study was determined to establish a corre-
lation with disease development in FAP patients. All six-
teen SNPs were in Hardy-Weinberg equilibrium (HWE).
Genotype frequency of the sixteen SNPs, results of simple
logistic regression and Kaplan-Meier analysis can be seen
in Table 1. In summary, an association between age of
diagnosis of CRC and genotypes can be seen for SNP
rs2578189 (Log-rank p = 0.0014, Wilcoxon p = 0.0004 and
Tarone-Ware p = 0.0009) with individuals harbouring the
variant genotype (TT) developing CRC 29 years earlier
than patients harbouring the wildtype genotype (CC),
median age of diagnosis of CRC is 74 years for genotype
CC, 55 years for genotype CT and 45 years for genotype
TT. Even though logistic regression did not show a sig-
nificant influence of this SNP on risk of developing CRC
(see Table 1), a multiple logistic regression was performed
to adjust for gender and mutation group; a trend towards
the variant genotype increasing your risk of CRC was ob-
served (HR = 7.85, 95% CI = 0.86-71.89, p = 0.068), which
seems to be influenced by mutation group (p = 0.028) and
not gender (p = 0.296).
Cox proportional hazard regression (adjusted for gender
and mutation group) further demonstrates that individuals
harbouring the variant genotype of SNP rs2578189 are at
higher instantaneous risk (increased hazard) compared to
individuals harbouring the wildtype genotype (hazard ratio
(HR) = 13.79, 95% CI = 2.36-80.64, p = 0.004). Our results
indicate that the variant genotype of SNP rs2578189 in
the ATP5A1 gene is a possible modifier of cancer develop-
ment in Australian FAP patients. We therefore recruited
an independent Dutch FAP cohort for validation analysis.
Validation studies of the observed association
The results from the independent Dutch FAP cohort for
SNP rs2578189 can be seen in Table 2. The association
between age of diagnosis of CRC and SNP rs2578189
genotypes seen in the Australian FAP cohort was not
observed in the Dutch FAP cohort. Neither is the
increased risk of CRC observed with Cox proportional
hazard regression when the variant genotype of SNP
rs2578189 is compared to the wildtype genotype: CRC
as endpoint of analysis (HR = 0.91, 95% CI = 0.15-5.65,
p = 0.915) or adenomas as endpoint of analysis (HR = 0.98,
95% CI = 0.42-2.32, p = 0.973).
Table 1 Logistic regression and Kaplan-Meier analysis
Logistic regression model (n = 139) Analysis endpoint - CRC Analysis endpoint - Adenomas
APT5A1SNP: Genotype Total n (%) Cancer free (n) CRC (n) Adenomas (n) OR (95% CI) p-value Kaplan-Meier analysis
p-value*
OR (95% CI) p-value Kaplan-Meier analysis
p-value*
rs13381709: CC 59 (42) 51 8 44 1.0
0.3183
1.0
0.2561CT 57 (41) 46 11 42 1.52 (0.56-4.12) 0.406 0.95 (0.42-2.19) 0.913
TT 23 (17) 22 1 13 0.29 (0.03-2.46) 0.256 0.44 (0.16-1.22) 0.115
rs1800636: CC 59 (42) 51 8 44 1.0
0.3183
1.0
0.2561CT 57 (41) 46 11 42 1.52 (0.56-4.12) 0.406 0.95 (0.42-2.19) 0.913
TT 23 (17) 22 1 13 0.29 (0.03-2.46) 0.256 0.44 (0.16-1.22) 0.115
rs1800637: TT 58 (42) 50 8 44 1.0
0.5385
1.0
0.2362TC 56 (40) 46 10 41 1.36 (0.49-3.74) 0.553 0.87 (0.37-2.02) 0.746
CC 25 (18) 23 2 14 0.54 (0.11-2.76) 0.462 0.40 (0.15-1.09) 0.074
rs1800639: GG 59 (42) 51 8 44 1.0
0.3183
1.0
0.2561GT 57 (41) 46 11 42 1.52 (0.56-4.12) 0.406 0.95 (0.42-2.19) 0.913
TT 23 (17) 22 1 13 0.29 (0.03-2.46) 0.256 0.44 (0.16-1.22) 0.115
rs1800640: TT 57 (41) 49 8 44 1.0
0.3183
1.0
0.2561TC 57 (41) 46 11 42 1.52 (0.56-1.12) 0.406 0.95 (0.42-2.19) 0.913
CC 23 (17) 22 1 13 0.29 (0.03-2.46) 0.256 0.44 (0.16-1.22) 0.115
Failed genotyping 2 (1)
rs2298787: TT 57 (41) 50 7 42 1.0
0.3208
1.0
0.4143TC 59 (42) 47 12 44 1.82 (0.66-5.03) 0.245 1.05 (0.46-2.41) 0.913
CC 23 (17) 22 1 13 0.32 (0.04-2.80) 0.306 0.46 (0.17-1.28) 0.138
rs2578187: GG 114 (82) 99 15 78 1.0
0.9719
1.0
0.5744GA 24 (17) 19 5 20 1.74 (0.56-5.35) 0.336 2.31 (0.74-7.24) 0.152
AA 1 (1) 1 0 1 - - - -
rs2578189: CC 89 (64) 78 11 67 1.0
0.0014
1.0
0.3898CT 45 (32) 38 7 28 1.31 (0.47-3.64) 0.609 0.54 (0.25-1.17) 0.118
TT 5 (4) 3 2 4 4.73 (0.71-31.52) 0.109 1.31 (0.14-12.38) 0.812
rs7244921: TT 59 (42) 51 8 44 1.0
0.3183
1.0
0.2561TC 57 (41) 46 11 42 1.52 (0.56-4.12) 0.406 0.95 (0.42-2.19) 0.913
CC 23 (17) 22 1 13 0.29 (0.03-2.46) 0.256 0.44 (0.16-1.22) 0.115
rs8088881: TT 58 (42) 50 8 44 1.0
0.3179
1.0
0.2493TC 57 (41) 46 11 42 1.49 (0.55-4.04) 0.429 0.89 (0.38-2.07) 0.788



















Table 1 Logistic regression and Kaplan-Meier analysis (Continued)
Failed genotyping 1 (1)
rs8089150: AA 57 (41) 50 7 42 1.0
0.3208
1.0
0.4143AG 59 (42) 47 12 44 0.82 (0.66-5.03) 0.245 1.05 (0.46-2.41) 0.913
GG 23 (17) 22 1 13 0.32 (0.04-2.80) 0.306 0.46 (0.17-1.28) 0.138
rs8092674: CC 59 (42) 51 8 44 1.0
0.3183
1.0
0.2561CT 57 (41) 46 11 42 1.52 (0.56-4.12) 0.406 0.95 (0.42-2.19) 0.913
TT 23 (17) 22 1 13 0.29 (0.03-2.46) 0.256 0.44 (0.16-1.22) 0.115
rs8093880: CC 57 (41) 49 8 43 1.0
0.3322
1.0
0.3575CT 55 (40) 45 10 42 1.36 (0.49-3.75) 0.551 1.05 (0.44-2.50) 0.909
TT 23 (17) 22 1 13 0.28 (0.03-2.36) 0.241 0.42 (0.15-1.18) 0.099
Failed genotyping 4 (3)
rs8094902: TT 59 (42) 51 8 44 1.0
0.3183
1.0
0.2561TC 57 (41) 46 11 42 1.52 (0.56-4.12) 0.406 0.95 (0.42-2.19) 0.913
CC 23 (17) 22 1 13 0.29 (0.03-2.46) 0.256 0.44 (0.16-1.22) 0.115
rs8095031: TT 59 (42) 51 8 44 1.0
0.3234
1.0
0.2221TC 57 (41) 46 11 42 1.52 (0.56-4.12) 0.406 0.95 (0.42-2.19) 0.913
CC 22 (16) 22 1 12 0.30 (0.04-2.58) 0.275 0.41 (0.15-1.14) 0.087
Failed genotyping 1 (1)
rs8095608: AA 58 (42) 51 7 43 1.0
0.3183
1.0
0.3738AG 58 (42) 46 12 43 1.90 (0.68-5.24) 0.214 1.0 (0.44-2.30) 1.000
GG 22 (16) 21 1 12 0.35 (0.04-2.99) 0.336 0.42 (0.15-1.17) 0.096
Failed genotyping 1 (1)
*Log-Rank p-value.
Demographics of the genotype frequencies in Australian FAP patients with CRC, patients with adenomas and cancer/adenoma free individuals. Logistic regression model was used to test risk of CRC associated with
each SNP, while Kaplan-Meier estimator analysis was used to test association between age of diagnosis of CRC/adenomas and genotype. Two different analysis was performed; one using CRC as endpoint of analysis



















Table 2 Logistic regression and Kaplan-Meier analysis
Logistic regression model (n = 423) Analysis endpoint - CRC Analysis endpoint - Adenomas
APT5A1SNP: Genotype Total n (%) Cancer free (n) CRC (n) Adenomas (n) OR (95% CI) p-value Kaplan-Meier
analysis p-value*
OR (95% CI) p-value Kaplan-Meier
analysis p-value*
rs2578189: CC 325 (77) 287 38 313 1.0
0.8739
1.0
0.5916CT 89 (21) 81 8 87 0.75 (0.33-1.66) 0.473 1.53 (0.33-70.3) 0.585
TT 9 (2) 7 2 8 2.16 (0.43-10.77) 0.348 0.28 (0.03-2.45) 0.250
*Log-Rank p-value.
Demographics of the genotype frequencies in Dutch FAP patients with CRC, patients with adenomas, and cancer/adenoma free individuals. Logistic regression model was used to test risk of CRC associated with each
SNP, while Kaplan-Meier estimator analysis was used to test association between age of diagnosis of CRC/adenomas and genotype. Two different analyses were performed; one using CRC as endpoint of analysis and



















Figure 2 Kaplan-Meier estimated by adenoma phenotype using
CRC as end-point of analysis. The graph shows the effect the
adenoma phenotype has on age of diagnosis of CRC in Dutch FAP
patients. The adenoma-categories are: AFAP = <100 adenomas and
Classic FAP = 100 or more adenomas. A significant difference is
observed between adenoma phenotype and age of diagnosis of
CRC (Log-rank p = 0.0256), even though there is no difference
between ages of diagnosis of CRC and adenoma phenotypes can be
seen when 50% of the population is cancer free (AFAP = 55 years
and Classic FAP = 54 years). An increased risk of CRC for patients in
the Classic FAP compare to AFAP phenotype is observed: OR = 2.12,
95% CI = 1.14-3.92 and p = 0.017).
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Dutch FAP cohort is the extensive follow-up data from
the Netherlands about adenoma counts and surgical inter-
vention (284/427 Dutch patients have had surgery). As
surgery does not fully protect against CRC and adenoma-
category and mutation group are known to influence
disease development, we added these confounding factors as
co-variats (plus gender as this was done for the Australian
cohort) in the Cox proportional hazard regression model
for SNP rs2578189 but this did not change the outcome
of the analysis (CRC as endpoint of analysis; HR = 0.65,
95% CI = 0.11-3.98, p = 0.639 or adenomas as endpoint of
analysis; HR = 0.96, 95% CI = 0.41-2.28, p = 0.929).
Validation cohort – disease expression
As shown before [7-9,11], phenotypic variability exists
within families with FAP suggesting that beside the APC
genotype other factors also play a role in determining the
severity of polyposis and risk of CRC for FAP patients.
Even though no significant difference can be seen between
age of diagnosis of adenomas and adenoma phenotype
(AFAP vs. Classic FAP; log-rank p = 0.892, see Figure 1),
the risk of CRC could still be influenced by the number of
adenomas. We observed a significant difference between
age of diagnosis of CRC and adenoma phenotype, see
Figure 2 (Log-rank p = 0.0256, Wilcoxon p = 0.0083 and
Tarone-Ware p = 0.0124), with individuals developing
more adenomas (Classic FAP, 100 or more adenomas)
developing CRC earlier than AFAP (<100 adenomas).
Logistic regression shows that individuals with Classic
FAP phenotype are at increased risk of CRC compared
to AFAP phenotype; OR = 2.12, 95% CI = 1.14-3.92,Figure 1 Kaplan-Meier estimated by adenoma phenotype using
adenomas as end-point of analysis. The graph shows the effect the
adenoma phenotype has on age of diagnosis of adenomas in Dutch
FAP patients. The adenoma-categories are: AFAP = <100 adenomas and
Classic FAP = 100 or more adenomas. No significant difference can be
seen between adenoma phenotype AFAP (24 years) and Classic FAP
(25 years); Log-rank p= 0.8923.p = 0.017. This is in accordance with previously reported
results where an increased risk of CRC and earlier ages of
diagnosis is associated with greater number of adenomas
[9,11,22]. We also adjusted this analysis according to gen-
der, surgery and mutation group of the patients, as this
are all confounding factors that can possibly influence an
individual’s risk of developing CRC. Multiple logistic re-
gression model did not display an increased risk of CRC
(OR = 0.90, 95% CI = 0.46-1.77, p = 0.764), but shows that
patients who have had interventional surgery are at in-
creased risk of CRC (OR = 14.83, 95% CI = 3.34-65.91 and
p ≤ 0.001) indicating that one adenoma phenotype has had
more surgery than the other group, which is correct as
94% of Classic FAP patients have had surgery vs. 42% of
AFAP patients. Simple (HR = 1.78, 95% CI = 0.88-3.62,
p = 0.107) and multiple (HR = 1.14, 95% CI = 0.56-2.35,
p = 0.706) Cox proportional hazard regression similarly
display no significant increased risk of CRC according to
adenoma phenotype, but again demonstrates that surgical
intervention (p = 0.015) are a marker for the more severe
polyposis phenotype (Classic FAP). This is also the case
for mutation group; APC MCR (p ≤ 0.001).
The severity of polyposis and early onset CRC is
dependent on the location of APC mutations [7,13]. The
Dutch FAP patients with mutations in the APC MCR
develops CRC 13 years earlier than patients with muta-
tions in the rest of the APC gene, while patients with
mutations in APC AFAP regions develops CRC later
Talseth-Palmer et al. Hereditary Cancer in Clinical Practice 2013, 11:20 Page 8 of 10
http://www.hccpjournal.com/content/11/1/20compared to individuals with mutations in the rest of
the APC gene (log-rank p ≤ 0.0001, see Figure 3A). The
same is observed when adenomas is used as endpoint of
analysis with patients developing adenomas at ages; APC
AFAP = 35 years, APC = 24 years and MCR = 15 years
(log-rank p ≤ 0.0001, see Figure 3B). Cox proportional
hazard regression also shows an increased risk of CRC
and adenomas for patients with mutations in APC MCR
compared to patients with mutations in the rest of the
APC gene (APC mutation category): CRC (HR = 7.35, 95%
CI = 2.44-22.14 and p ≤ 0.001) and adenomas (HR = 2.36,
95% CI = 1.54-3.61 and p ≤ 0.001). We also adjusted thisFigure 3 Kaplan-Meier estimated by location of APC mutation. A) Usin
of the APC mutation has on age of diagnosis of CRC in Dutch FAP patients. A
intermediate (APC, 53 years) and severe (MCR, 40 years) polyposis phenotype
graph shows the effect the location of the APC mutation has on age of diagn
observed between the attenuated (APC AFAP, 35 years), intermediate (APC, 24analysis for gender, surgery and adenoma phenotype – the
results are still significant; CRC (HR = 7.71, 95% CI = 2.53-
23.49 and p ≤ 0.001) and adenomas (HR = 2.71, 95%
CI = 1.72-4.29 and p ≤ 0.001) and are influenced by whe-
ther the patients have had surgery (CRC p = 0.015 and
adenomas p ≤ 0.001), not gender (CRC p = 0.869 and ade-
nomas p = 0.923) or adenoma phenotype (CRC p = 0.706
and adenomas p = 0.055). Not surprisingly, this is showing
us that interventional surgery is the biggest marker for
patients with mutations in APC MCR and are therefore at
higher risk of CRC. As expected, a decreased risk of CRC
and adenomas is observed for patients with mutations ing CRC as end-point of analysis: The graph shows the effect the location
significant difference is observed between the attenuated (APC AFAP),
; Log-rank p≤ 0.0001. B) Using adenomas as end-point of analysis: The
osis of adenomas in Dutch FAP patients. A significant difference is
years) and severe (MCR, 15 years) polyposis phenotype; Log-rank p≤ 0.0001.
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tions in the rest of the APC gene: CRC (HR = 0.28, 95%
CI = 0.10-0.78 and p = 0.015) and adenomas (HR = 0.49,
95% CI = 0.33-0.73 and p ≤ 0.001).
The risk of developing CRC in FAP patients is conside-
rably different from the most common genetic predis-
position to CRC, Lynch syndrome, with earlier ages of
disease onset and close to 100% penetrance if left un-
treated. Lynch syndrome cases that are not under surveil-
lance are usually identified when they present with CRC
whereas FAP patients initially present with adenomas that
are removed before the development of CRC and often
undergo total colectomy to reduce the risk of cancer
development. The timing of surgery may have influenced
adenoma counts such that some patients may have, if left
untreated, developed many more adenomas than that
identified at colectomy. For this reason, it is much more
difficult to study CRC risk and differences in the pheno-
typic expression in FAP patients as many of them will
have interventional surgery to reduce their risk of devel-
oping CRC. This could possibly explain the differences
observe between the Dutch and Australian patient data, as
we have access to extensive follow-up and surveillance
data from the Dutch FAP patients that are not available
for the Australian patients.
Atp5a1 in mice is located on the same chromosome as
Apc, linked in the cis configuration on chromosome 18.
The modifier locus acts in a dominant fashion to markedly
reduce intestinal polyp multiplicity in mice with Apc
mutations [26]. One of the reasons why we cannot conclu-
sively associate ATP5A1 in FAP patients with adenoma
counts or disease risk could be that in humans APC is
located on chromosome 5, while ATP5A1 is located on
chromosome 18.
Conclusion
These results highlight the difficulties in studying a disease
that has a high degree of intervention and also emphasize
the importance of large sample sizes when searching for
modifier genes in patients with an inherited predisposition
to disease. To fully determine if there are genetic modi-
fiers of disease in FAP we would encourage people that
are interested in collaborating in future studies into the
role of modifier genes in disease expression in FAP to join
forces. Even though we were not able to associate SNPs of
ATP5A1 with FAP, there remains the possibility that there
are genetic modifiers that influence disease severity in
FAP due to the differences observed in disease expression.
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